Your new experience awaits. Try the new design now and help us make it even better

SYSTEMATIC REVIEW article

Front. Pharmacol., 04 June 2024

Sec. Pharmacology of Anti-Cancer Drugs

Volume 15 - 2024 | https://doi.org/10.3389/fphar.2024.1378577

RETRACTED: Concomitant use of renin-angiotensin system inhibitors augments the efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis

Retracted
Junjie YuJunjie Yu1Fangang MengFangang Meng1Wenxia SuiWenxia Sui1Junmin Yu
Junmin Yu2*Jinhai Shen
Jinhai Shen3*
  • 1Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
  • 2Department of Pain Treatment, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
  • 3Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, Jiangsu, China

This article has been retracted. Please follow the link to the full retraction notice for details.

Citation: Yu J, Meng F, Sui W, Yu J and Shen J (2024) Concomitant use of renin-angiotensin system inhibitors augments the efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Front. Pharmacol. 15:1378577. doi: 10.3389/fphar.2024.1378577

Received: 29 January 2024; Accepted: 17 May 2024;
Published: 04 June 2024.; Retracted: 07 November 2025.

Edited by:

Rakesh K. Jain, Massachusetts General Hospital and Harvard Medical School, United States

Reviewed by:

Benjamin Wolf, Leipzig University, Germany
Nathan Andrew Holland, Texas Tech University Health Sciences Center El Paso, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.